China: Life Sciences, Biotechnology & Nanotechnology

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

China Healthcare

AO

A&O Shearman

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection...

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

On January 23, 2025, the Anti-Monopoly and Anti-Unfair Competition Commission under China's State Council officially released the PRCAnti-Monopoly Guidelines for the Pharmaceutical Sector...

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

In the age of globalization, Chinese pharmaceutical companies are at the forefront of innovation and collaboration, seizing unprecedented development opportunities.

China Healthcare

HK

Han Kun Law Offices

揭秘中国创新药企NewCo模式实战中的"六脉神剑"

China Healthcare

HK

Han Kun Law Offices

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

《关于药品领域的反垄断指南》解读：药企反垄断风险"划重点"

China Healthcare

AB

AnJie Broad Law Firm

China On The Move: Lessons From China's 2024 National Negotiation Of Drug Prices

China Healthcare

GT

Greenberg Traurig, LLP

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

Circular On The Work Relating To The Implementation Of GB 9706.1-2020 And Supporting Concurrent Standards And Special Standards

China Healthcare

CC

CMS, China

Measures For Supervision And Administration Of The Quality Of Drug Supply And Use

China Healthcare

CC

CMS, China

Further Strengthening The Supervision Of Entrusted Manufacturing Of Medical Devices: Key Takeaways From NMPA's New Notice

China Healthcare

CC

CMS, China

第三国制造的美国海关核查风险

China International

AB

AnJie Broad Law Firm

商标注册满三年，起算点到底如何计算？

K

Kangxin

News & Cases From China: February 2025

China Litigation

R

Rouse

The Global Challenge Of Antimicrobial Resistance: Patent Filing Analysis A Decade On

MC

Marks & Clerk

Cayman Short Form Merger – Is It A Loophole?

Worldwide Commercial

A

Appleby

Food and Drugs Law

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

China Healthcare

AO

A&O Shearman

马库什化合物专利申请中，这4个缺陷一定要规避！

马库什化合物是一类基于一定基础结构的前体下...

K

Kangxin

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection...

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

转用发明创造性浅析

CP

CCPIT Patent & Trademark Law Office

从"AB酶"系列案件看商标法第十条一款七项的适用

CP

CCPIT Patent & Trademark Law Office

See more

Life Sciences, Biotechnology & Nanotechnology

Six Key Insights Into China Biotech's NewCo Model

In the age of globalization, Chinese pharmaceutical companies are at the forefront of innovation and collaboration, seizing unprecedented development opportunities.

China Healthcare

HK

Han Kun Law Offices

揭秘中国创新药企NewCo模式实战中的"六脉神剑"

在全球化背景之下，中国医药企业正站在创新与合作的新风口，迎接前所未有的发展契机。与此同时，海外投资者与医药企业亦在敏锐捕捉投$

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

Application Of Bioisosterism In The Judgment Of Inventiveness

AC

AFD China

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

医药企业申请商标的注意事项

CP

CCPIT Patent & Trademark Law Office

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

See more

Healthcare

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

China Healthcare

AO

A&O Shearman

里程碑式判决：经营者集中行政诉讼"第一案"代理有感

某某药业有限公司（"某某药业公司"）与北京某药业有限公司（"北京某药业公司"）之间就股权交易的争议由来已久。双方争议涉及股权买卖纠纷

China Anti-trust

AB

AnJie Broad Law Firm

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.

R

Rouse

China Newsletter | Q4 2024/Issue No. 62

China International

GT

Greenberg Traurig, LLP

China Unveils New Anti-Monopoly Guidelines For The Pharmaceutical Sector

China Anti-trust

JD

Jones Day

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

China Tightens The Reins: Anti-Corruption Compliance Expectations For Companies In The Healthcare Sector

RG

Ropes & Gray LLP

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More